Endocrinology and Metabolism

Original Articles

Thyroid
Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients: Jiyeon Ahn, Min Kyung Lee, Jae Hyuk Lee, Seo Young Sohn; Endocrinol Metab. 2021;36(4):769-777. Published online August 27, 2021; DOI: https://doi.org/10.3803/EnM.2021.1109

4,359 View
185 Download
17 Web of Science
18 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Data on the association between coronavirus disease 2019 (COVID-19) and thyroid have been reported, including overt thyrotoxicosis and suppression of thyroid function. We aimed to evaluate the thyroid hormone profile and its association with the prognosis of COVID-19 in Korean patients.
Methods
The clinical data of 119 patients with COVID-19, admitted in the Myongji Hospital, Goyang, South Korea, were retrospectively evaluated. The thyroid hormone profiles were analyzed and compared based on disease severity (non-severe disease vs. severe to critical disease). Clinical outcomes were analyzed according to the tertiles of thyroid hormones.
Results
Of the 119 patients, 76 (63.9%) were euthyroid, and none presented with overt thyroid dysfunction. Non-thyroidal illness syndrome was the most common manifestation (18.5%), followed by subclinical thyrotoxicosis (14.3%) among patients with thyroid dysfunction. Thyroid stimulating hormone (TSH) and triiodothyronine (T3) levels were significantly lower in patients with severe to critical disease than in those with non-severe disease (P<0.05). Patients in the lowest T3 tertile (<0.77 ng/mL) had higher rates of mechanical ventilation, intensive care unit admission, and death than those in the middle and highest (>1.00 ng/mL) T3 tertiles (P<0.05). COVID-19 patients in the lowest T3 tertile were independently associated with mortality (hazard ratio, 5.27; 95% confidence interval, 1.09 to 25.32; P=0.038) compared with those in the highest T3 tertile.
Conclusion
Thyroid dysfunction is common in COVID-19 patients. Changes in serum TSH and T3 levels may be important markers of disease severity in COVID-19. Decreased T3 levels may have a prognostic significance in COVID-19 related outcome.

Citations

Citations to this article as recorded by

The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
Sadra Ashrafi, Hossein Hatami, Razieh Bidhendi-Yarandi, Mohammad Hossein Panahi
BMC Endocrine Disorders.2024;[Epub] CrossRef
Thyroid Stimulating Hormone as a Possible Additional COVID-19 Outcome Marker
Anamarija Zrilic Vrkljan, Ana Majic Tengg, Tanja Palaversa, Srecko Marusic, Lana Ruzic, Ines Bilic-Curcic, Maja Cigrovski Berkovic
Medicina.2024; 60(2): 314. CrossRef
Effect of Hypothalamic Adrenal Axis and Thyroid Function Alterations on Prognosis of Critically Ill COVID-19 Patients
Muhammet KORKUSUZ, Sulbiye KARABURGU, Tayfun ET, Rafet YARIMOĞLU, Nuh KUMRU
Namık Kemal Tıp Dergisi.2024; 12(1): 17. CrossRef
Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis
Ziqi Li, Pengwei Hou, Shuwen Mu, Renzhi Wang, Hui Miao, Ming Feng, He Wang, Wentai Zhang, Yihao Chen, Tianshun Feng, Shousen Wang, Yi Fang
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Influence of SARS-CoV-2 Infection on the Thyroid Gland
Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski
Biomedicines.2023; 11(2): 614. CrossRef
Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study
Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara
Hormone and Metabolic Research.2023; 55(03): 169. CrossRef
The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity?
Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran
Endocrine Research.2023; 48(2-3): 44. CrossRef
Transient low T3 syndrome in patients with COVID-19: a new window for prediction of disease severity
Mingyao Zhong, Yue Gao, Hongling Hu, Xuan Zhu, Lulu Gan, Ling Li, Cheng Xiang, Yimin Yan, Zhe Dai
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis
Yiru Chen, Xiuneng Li, Yu Dai, Jingjing Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
Diagnostics.2022; 12(4): 960. CrossRef
Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19
Stephani C. Wang, Fengmin Zhang, Hui Zhu, Haipeng Yang, Yang Liu, Ping Wang, Vladimir Parpura, Yu-Feng Wang
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Association Between FT3 With the Outcome and Inflammation/Coagulopathy/Fibrinolysis of COVID-19
Jiayi Deng, Siye Zhang, Fei Peng, Quan Zhang, Yi Li, Yanjun Zhong
Frontiers in Endocrinology.2022;[Epub] CrossRef
Primary hypothyroidism with an episode of ventricular tachycardia in a patient with COVID-19
Pin-Hsu Liao, Yu-Cheng Cheng, Po-Yu Liu, I-Te Lee
Medicine.2022; 101(25): e29243. CrossRef
Low triiodothyronine syndrome is associated with stroke‐associated pneumonia
Huijun Chen, Minjie Xu, Yezhi Huang, Jincai He, Wenwei Ren
European Journal of Clinical Investigation.2022;[Epub] CrossRef
Association of thyroid dysfunction and COVID-19: A systematic review and meta-analysis
Mohammad Darvishi, Mohammad Reza Nazer, Hamze Shahali, Majid Nouri
Frontiers in Endocrinology.2022;[Epub] CrossRef
The prognostic utility of serum thyrotropin in hospitalized Covid-19 patients: statistical and machine learning approaches
E. Pappa, P. Gourna, G. Galatas, M. Manti, A. Romiou, L. Panagiotou, R. Chatzikyriakou, N. Trakas, G. Feretzakis, C. Christopoulos
Endocrine.2022; 80(1): 86. CrossRef
Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge
Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud
Life.2022; 12(12): 2014. CrossRef
COVID-19 and thyroid function: What do we know so far?
Camila Lüdke Rossetti, Juliana Cazarin, Fabio Hecht, Fabyan Esberard de Lima Beltrão, Andrea Cláudia Freitas Ferreira, Rodrigo Soares Fortunato, Helton Estrela Ramos, Denise Pires de Carvalho
Frontiers in Endocrinology.2022;[Epub] CrossRef

Clinical Study
The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies: Seo Young Sohn, Eunyoung Lee, Min Kyung Lee, Jae Hyuk Lee; Endocrinol Metab. 2020;35(4):786-800. Published online November 25, 2020; DOI: https://doi.org/10.3803/EnM.2020.728

6,053 View
288 Download
20 Web of Science
22 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Whether hyperthyroidism is an independent risk factor for cardiovascular events remains controversial. We aimed to evaluate the association of overt and subclinical hyperthyroidism with the risk of ischemic heart disease (IHD), stroke, heart failure, and cardiovascular mortality.
Methods
Studies regarding the association between hyperthyroidism and cardiovascular events were searched on PubMed and Embase databases. The cardiovascular disease (CVD) risk was classified as high and low, based on pre-existing diseases, including history of coronary, cerebral, or peripheral artery disease; heart failure; atrial fibrillation; diabetes mellitus; or chronic kidney disease.
Results
Thirty-seven cohort studies were included in this meta-analysis. The pooled hazard ratio for subjects with overt hyperthyroidism compared with the control group was 1.11 (95% confidence interval [CI], 1.03 to 1.19) for IHD, 1.35 (95% CI, 1.03 to 1.75) for stroke, and 1.20 (95% CI, 1.00 to 1.46) for cardiovascular mortality. For subjects with subclinical hyperthyroidism, the pooled hazard ratio was 1.24 (95% CI, 1.07 to 1.45) for IHD, when compared with the control group. Subgroup analysis by CVD risk showed that the risk of stroke in overt hyperthyroidism was increased in the low CVD risk group; however, these association was not observed in the high CVD risk group. Similarly, the risk of IHD in subjects with subclinical hyperthyroidism was significantly increased in the low CVD risk group.
Conclusion
Overt hyperthyroidism is associated with increased risk of IHD, stroke, and cardiovascular mortality, and subclinical hyperthyroidism is associated with increased risk of IHD. These associations were particularly observed in the low risk CVD group without underlying CVD.

Citations

Citations to this article as recorded by

Trends in Prevalence of Thyroid Dysfunction and its Associations With Mortality Among US Participants, 1988-2012
Xiaowen Zhang, Yong Wang, Hongwei Wang, Xinlin Zhang
The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e657. CrossRef
Adequacy of thyroid hormone replacement for people with hypothyroidism in real‐world settings: A systematic review and meta‐analysis of observational studies
Agathoklis Efthymiadis, Matthew Henry, Dimitrios Spinos, Marianthi Bourlaki, Alexandros Tsikopoulos, Angeliki Bourazana, Anastasios Bastounis, Konstantinos Tsikopoulos
Clinical Endocrinology.2024; 100(5): 488. CrossRef
Thyroid Disorders and Peripheral Arterial Disease
Katica Bajuk Studen, Simona Gaberscek, Katja Zaletel, Ales Blinc, Miso Sabovic, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani, Mojca Jensterle, Dimitri P Mikhailidis, Pavel Poredos
Current Vascular Pharmacology.2024; 22(1): 36. CrossRef
Higher Risk of Incident Hyperthyroidism in Patients With Atrial Fibrillation
Pang-Shuo Huang, Jen-Fang Cheng, Jien-Jiun Chen, Yi-Chih Wang, Juey-Jen Hwang, Cho-Kai Wu, Chia-Ti Tsai
The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): 92. CrossRef
Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)
I. E. Chazova, N. M. Chikhladze, N. V. Blinova, Zh. E. Belaya, N. M. Danilov, E. M. Elfimova, A. Yu. Litvin, L. Ya. Rozhinskaya, N. Yu. Sviridenko, M. Yu. Shvetsov, V. A. Azizov, E. A. Grigorenko, N. P. Mit’kovskaja, I. I. Mustafaev, A. G. Polupanov, A. S
Eurasian heart journal.2023; (1): 6. CrossRef
Sympathetic Activation Promotes Cardiomyocyte Apoptosis in a Rabbit Susceptibility Model of Hyperthyroidism-Induced Atrial Fibrillation via the p38 MAPK Signaling Pathway
Jialin Zheng, Shijian Zhao, Qishi Yang, Yantao Wei, Jianmei Li, Tao Guo
Critical Reviews in Eukaryotic Gene Expression.2023; 33(5): 17. CrossRef
Cardiovascular outcomes in subclinical thyroid disease: an update
Matthew D. Ettleson
Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(5): 218. CrossRef
Lower free triiodothyronine levels are associated with higher all-cause and cardiovascular mortality in people with diabetes-NHANES 2007–2012
Chang Liu, Zhong Xin, Lin Hua
Diabetes Research and Clinical Practice.2023; 202: 110811. CrossRef
Hyperthyroidism
Sun Y. Lee, Elizabeth N. Pearce
JAMA.2023; 330(15): 1472. CrossRef
Is Thyroid Dysfunction Associated with Unruptured Intracranial Aneurysms? A Population-Based, Nested Case–Control Study from Korea
Hyeree Park, Sun Wook Cho, Sung Ho Lee, Kangmin Kim, Hyun-Seung Kang, Jeong Eun Kim, Aesun Shin, Won-Sang Cho
Thyroid®.2023; 33(12): 1483. CrossRef
Risks of suboptimal and excessive thyroid hormone replacement across ages
U. Feldt-Rasmussen, G. Effraimidis, S. Bliddal, M. Klose
Journal of Endocrinological Investigation.2023; 47(5): 1083. CrossRef
Association of Mild Thyroid Dysfunction and Adverse Prognosis Among Chinese Patients With Acute ST Segment Elevation Myocardial Infarction
Mei-Fang Li, Ze-Tao Wei, Shuai Li, Qi-Ming Feng, Jing-Bo Li
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Cardiovascular Effects of Subclinical Hyperthyroidism following Percutaneous Coronary Intervention
Ricardo Correa, Ricardo Villela
Clinical Thyroidology.2022; 34(6): 240. CrossRef
Weight Gain and Body Composition Changes during the Transition of Thyroid Function in Patients with Graves’ Disease Undergoing Radioiodine Treatment
Zhenqin Cai, Qiyu Chen, Yan Ling, Henrik Falhammar
International Journal of Endocrinology.2022; 2022: 1. CrossRef
Minor perturbations of thyroid homeostasis and major cardiovascular endpoints—Physiological mechanisms and clinical evidence
Patrick Müller, Melvin Khee-Shing Leow, Johannes W. Dietrich
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Role of thyroid hormones-induced oxidative stress on cardiovascular physiology
María Laura Barreiro Arcos
Biochimica et Biophysica Acta (BBA) - General Subjects.2022; 1866(12): 130239. CrossRef
Yearly Incidence of Stroke and Bleeding in Atrial Fibrillation with Concomitant Hyperthyroidism: A National Discharge Database Study
Juqian Zhang, Arnaud Bisson, Grégoire Fauchier, Alexandre Bodin, Julien Herbert, Pierre Henri Ducluzeau, Gregory Y. H. Lip, Laurent Fauchier
Journal of Clinical Medicine.2022; 11(5): 1342. CrossRef
Platelet abnormalities in autoimmune thyroid diseases: A systematic review and meta-analysis
Yu-tian Cao, Kai-yu Zhang, Jing Sun, Yan Lou, Tian-su Lv, Xinyi Yang, Wen-hui Zhang, Jiang-yi Yu, Qi-biao Wu, Xi-qiao Zhou
Frontiers in Immunology.2022;[Epub] CrossRef
Subclinical Hyperthyroidism: A Review of the Clinical Literature
Karen Tsai, Angela M. Leung
Endocrine Practice.2021; 27(3): 254. CrossRef
Thyroid and heart, a clinically relevant relationship
G. Corona, L. Croce, C. Sparano, L. Petrone, A. Sforza, M. Maggi, L. Chiovato, M. Rotondi
Journal of Endocrinological Investigation.2021; 44(12): 2535. CrossRef
Antithyroid Drug Treatment in Graves’ Disease
Jae Hoon Chung
Endocrinology and Metabolism.2021; 36(3): 491. CrossRef
Cardiovascular Outcomes in Thyroid Cancer Patients Treated With Thyroidectomy: A Meta-Analysis
Eun Kyung Lee, Hwa Young Ahn, Eu Jeong Ku, Won Sang Yoo, Young Ki Lee, Kee-Hyun Nam, Young Jun Chai, Shinje Moon, Yuh-Seog Jung
The Journal of Clinical Endocrinology & Metabolism.2021;[Epub] CrossRef

Clinical Study
Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective: Seo Young Sohn, Hye Won Jang, Yoon Young Cho, Sun Wook Kim, Jae Hoon Chung; Endocrinol Metab. 2015;30(4):531-542. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.531

3,542 View
43 Download
9 Web of Science
8 Crossref

Abstract PDF PubReader

Background

Previous studies have suggested that recombinant human thyroid stimulating hormone (rhTSH) stimulation is an acceptable alternative to thyroid hormone withdrawal (THW) when radioiodine remnant ablation is planned for thyroid cancer treatment, based on superior short-term quality of life with non-inferior remnant ablation efficacy. This study evaluated the cost-effectiveness of radioiodine remnant ablation using rhTSH, compared with the traditional preparation method which renders patients hypothyroid by THW, in Korean perspective.

Methods

This economic evaluation considered the costs and benefits to the Korean public healthcare system. Clinical experts were surveyed regarding the current practice of radioiodine ablation in Korea and their responses helped inform assumptions used in a cost effectiveness model. Markov modelling with 17 weekly cycles was used to assess the incremental costs per quality-adjusted life year (QALY) associated with rhTSH. Clinical inputs were based on a multi-center, randomized controlled trial comparing remnant ablation success after rhTSH preparation with THW. The additional costs associated with rhTSH were considered relative to the clinical benefits and cost offsets.

Results

The additional benefits of rhTSH (0.036 QALY) are achieved with an additional cost of Korean won ₩961,105, equating to cost per QALY of ₩26,697,361. Sensitivity analyses had only a modest impact upon cost-effectiveness, with one-way sensitivity results of approximately ₩33,000,000/QALY.

Conclusion

The use of rhTSH is a cost-effective alternative to endogenous hypothyroid stimulation prior to radioiodine ablation for patients who have undergone thyroidectomy in Korea.

Citations

Citations to this article as recorded by

Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer
Sohyun Park, Ji-In Bang, Keunyoung Kim, Youngduk Seo, Ari Chong, Chae Moon Hong, Dong-Eun Lee, Miyoung Choi, Sang-Woo Lee, So Won Oh
Clinical Nuclear Medicine.2024; 49(3): e96. CrossRef
Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček, Rainer Görges
Cancers.2023; 15(9): 2510. CrossRef
Health-related quality of life of thyroid cancer patients undergoing radioiodine therapy: a cohort real-world study in a reference public cancer hospital in Brazil
Jayda Eiras Ramim, Marcella Araugio Soares Cardoso, Gessen Lopes Carneiro de Oliveira, Maria Luisa Gomes, Tiago Teixeira Guimarães, Rossana Corbo Ramalho de Mello, Anke Bergmann, Priscilla Brunelli Pujatti
Supportive Care in Cancer.2020; 28(8): 3771. CrossRef
Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer
Ewelina Szczepanek-Parulska, Magdalena Wojewoda-Korbelak, Martyna Borowczyk, Malgorzata Kaluzna, Barbara Brominska, Katarzyna Ziemnicka, Rafal Czepczynski, Maciej Baczyk, Marek Ruchala
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub] CrossRef
Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
Michaela A. Dinan, Yanhong Li, Shelby D. Reed, Julie Ann Sosa
Endocrine Practice.2019; 25(1): 31. CrossRef
Triennial Report ofEndocrinology and Metabolism, 2015 to 2017
Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee
Endocrinology and Metabolism.2018; 33(2): 195. CrossRef
Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer
Jeonghoon Ha, Min Hee Kim, Kwanhoon Jo, Yejee Lim, Ja Seong Bae, Sohee Lee, Moo Il Kang, Bong Yun Cha, Dong Jun Lim
Medicine.2017; 96(29): e7512. CrossRef
Does the Risk of Metabolic Syndrome Increase in Thyroid Cancer Survivors?
Min-Hee Kim, Jin-young Huh, Dong-jun Lim, Moo-Il Kang
Thyroid.2017; 27(7): 936. CrossRef

Thyroid
Weight Changes in Patients with Differentiated Thyroid Carcinoma during Postoperative Long-Term Follow-up under Thyroid Stimulating Hormone Suppression: Seo Young Sohn, Ji Young Joung, Yoon Young Cho, Sun Mi Park, Sang Man Jin, Jae Hoon Chung, Sun Wook Kim; Endocrinol Metab. 2015;30(3):343-351. Published online August 4, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.3.343

4,088 View
60 Download
10 Web of Science
14 Crossref

Abstract PDF PubReader

Background

There are limited data about whether patients who receive initial treatment for differentiated thyroid cancer (DTC) gain or lose weight during long-term follow-up under thyroid stimulating hormone (TSH) suppression. This study was aimed to evaluate whether DTC patients under TSH suppression experience long-term weight gain after initial treatment. We also examined the impact of the radioactive iodine ablation therapy (RAIT) preparation method on changes of weight, comparing thyroid hormone withdrawal (THW) and recombinant human TSH (rhTSH).

Methods

We retrospectively reviewed 700 DTC patients who underwent a total thyroidectomy followed by either RAIT and levothyroxine (T4) replacement or T4 replacement alone. The control group included 350 age-matched patients with benign thyroid nodules followed during same period. Anthropometric data were measured at baseline, 1 to 2 years, and 3 to 4 years after thyroidectomy. Comparisons were made between weight and body mass index (BMI) at baseline and follow-up.

Results

Significant gains in weight and BMI were observed 3 to 4 years after initial treatment for female DTC but not in male patients. These gains among female DTC patients were also significant compared to age-matched control. Women in the THW group gained a significant amount of weight and BMI compared to baseline, while there was no increase in weight or BMI in the rhTSH group. There were no changes in weight and BMI in men according to RAIT preparation methods.

Conclusion

Female DTC patients showed significant gains in weight and BMI during long-term follow-up after initial treatment. These changes were seen only in patients who underwent THW for RAIT.

Citations

Citations to this article as recorded by

Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial
Yang Jiang, Xiangju Sun, Maomin Jiang, Hewei Min, Jing Wang, Xinghua Fu, Jiale Qi, Zhenjie Yu, Xiaomei Zhu, Yibo Wu
Frontiers in Public Health.2024;[Epub] CrossRef
Thyroidectomy Effects on the Body Mass Index and Thyroid-Stimulating Hormone: A Systematic Review and Meta-Analysis
Hyder Mirghani, Ahmad M Fnjan, Abdullah F Almalki, Ali F Almadan, Omar Abdullah M Alammar, Abdulaziz S Alhwiati, Amer A Laradhi, Ahmed M Bakour, Mohamad A Aljahed, Abdulmajeed M Alzahrani
Cureus.2024;[Epub] CrossRef
Pre-surgery dietician counseling can prevent post-thyroidectomy body weight gain: results of an intervention trial
Laura Croce, Cristina Pallavicini, Noemi Busca, Benedetto Calì, Giuseppe Bellastella, Francesca Coperchini, Flavia Magri, Luca Chiovato, Hellas Cena, Mario Rotondi
Endocrine.2023; 81(2): 246. CrossRef
Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study
Floortje Mols, Dounya Schoormans, Romana Netea-Maier, Olga Husson, Sandra Beijer, Katrijn Van Deun, Wouter Zandee, Marleen Kars, Pleun C. M. Wouters van Poppel, Suat Simsek, Patrick van Battum, Jérôme M. H. Kisters, Jan Paul de Boer, Elske Massolt, Rachel
Thyroid Research.2023;[Epub] CrossRef
Effects of a low-iodine diet in post-thyroidectomy thyroid cancer patients undergoing I131 therapy at the Vietnam National Cancer Hospital
Bach Viet Hoang, Tien Thi Hong Nguyen, Yen Thi Duong, Hoa Thi Thanh Nguyen, Thu Ha Nguyen, Thanh Thi Nguyen, Lieu Thi Thu Nguyen, Huong Thi Le
Nutrition and Health.2023;[Epub] CrossRef
Positive effects of thyroid replacement therapy on assisted reproductive technology outcomes in women with subclinical hypothyroidism with positive thyroid peroxidase autoantibodies
Himanshu Arora, Ineabelle Collazo, Katherine L. Palmerola, Madhumita Parmar, Manish Narasimman, Nicholas Hendon, Juergen Eisermann, Maria Bustillo
F&S Reports.2022; 3(1): 32. CrossRef
Weight Gain After Thyroidectomy: A Systematic Review and Meta-Analysis
Christine N Huynh, Janina V Pearce, Le Kang, Francesco S Celi
The Journal of Clinical Endocrinology & Metabolism.2021; 106(1): 282. CrossRef
Weight change in patients with differentiated thyroid carcinoma after total thyroidectomy versus lobectomy
Hae-Ryong Cho, Ra-Yeong Song, Kyung Ho Kang
Korean Journal of Clinical Oncology.2020; 16(2): 127. CrossRef
Postthyroidectomy obesity in a Korean population: does the extent of surgery matter?
Min-Young Park, Sang Eun Nam, Kyoung Sik Park, Madhuri Saindane, Young-Bum Yoo, Jung-Hyun Yang, Ah-Leum Ahn, Jae-Kyung Choi, Won Seo Park
Annals of Surgical Treatment and Research.2019; 97(3): 119. CrossRef
Body weight change is unpredictable after total thyroidectomy
Ron Glick, Paula Chang, Peter Michail, Jonathan W. Serpell, Simon Grodski, James C. Lee
ANZ Journal of Surgery.2018; 88(3): 162. CrossRef
Weight Changes After Thyroid Surgery for Patients with Benign Thyroid Nodules and Thyroid Cancer: Population-Based Study and Systematic Review and Meta-Analysis
Naykky Singh Ospina, Ana Castaneda-Guarderas, Oksana Hamidi, Oscar J. Ponce, Wang Zhen, Larry Prokop, Victor M. Montori, Juan P. Brito
Thyroid.2018; 28(5): 639. CrossRef
Does the Risk of Metabolic Syndrome Increase in Thyroid Cancer Survivors?
Min-Hee Kim, Jin-young Huh, Dong-jun Lim, Moo-Il Kang
Thyroid.2017; 27(7): 936. CrossRef
Thyroid hormone and its metabolites in relation to quality of life in patients treated for differentiated thyroid cancer
E.T. Massolt, M. van der Windt, T.I.M. Korevaar, B.L.R. Kam, J.W. Burger, G.J.H. Franssen, I. Lehmphul, J. Köhrle, W.E. Visser, R.P. Peeters
Clinical Endocrinology.2016; 85(5): 781. CrossRef
High Serum Levels of Thyroid-Stimulating Hormone and Sustained Weight Gain in Patients with Thyroid Cancer Undergoing Radioiodine Therapy
Hyo Jung Seo, June-Key Chung, Keon Wook Kang, E. Edmund Kim, Gi Jeong Cheon, Jin Chul Paeng, Dong Soo Lee, Young Joo Park, Do Joon Park, Jae Gol Choe
International Journal of Thyroidology.2016; 9(1): 19. CrossRef

Frequency of RAS Mutations and PAX8/PPARgamma Rearrangement in Follicular Thyroid Tumors in Korea.: Hye Jeong Kim, Hye Won Jang, Seo Young Sohn, Yoon La Choi, Hee Jin Kim, Young Lyun Oh, Sun Wook Kim, Jae Hoon Chung; Endocrinol Metab. 2012;27(1):45-53. Published online March 1, 2012; DOI: https://doi.org/10.3803/EnM.2012.27.1.45

22,689 View
22 Download
3 Crossref

Abstract PDF

BACKGROUND
Follicular thyroid tumors harbor several genetic alterations such as RAS mutations and PAX8/PPARgamma rearrangement. The aims of our study were to investigate the prevalence of RAS mutations and PAX8/PPARgamma rearrangement in follicular thyroid tumors and to correlate RAS mutations and/or PAX8/PPARgamma rearrangement with clinicopathologic features in Korean patients with follicular thyroid carcinomas. METHODS: RAS mutations were investigated by polymerase chain reaction and DNA sequencing in surgical specimens of 37 follicular thyroid carcinomas (FTCs) and 16 follicular thyroid adenomas (FTAs). PAX8/PPARgamma rearrangement was analyzed by fluorescent in situ hybridization in surgical specimens of 31 FTCs and 13 FTAs. RESULTS: RAS mutations were detected in 30% (11 of 37) of FTCs and 19% (three of 16) of FTAs. Three of 11 FTC patients with RAS mutations died of thyroid cancer, but none of the 26 FTC patients without RAS mutations. PAX8/PPARgamma rearrangement was found in 10% (three of 31) of FTCs, but in none of the 13 FTAs. All three FTC patients with PAX8/PPARgamma rearrangement remained in complete remission during follow-up. There were no FTC patients with both RAS mutations and PAX8/PPARgamma rearrangement. CONCLUSION: The prevalence of RAS mutations in our series of follicular tumors was similar to previous studies. The frequency of PAX8/PPARgamma rearrangements in our group of FTC was lower than previous western reports, but higher than Japanese reports. RAS mutations may be associated with hematogeneous metastasis and poor survival while PAX8/PPARgamma rearrangement may be related to more favorable prognosis in Korean patients with FTCs.

Citations

Citations to this article as recorded by

Preoperative serum thyroglobulin and changes in serum thyroglobulin during TSH suppression independently predict follicular thyroid carcinoma in thyroid nodules with a cytological diagnosis of follicular lesion
Hye Jeong Kim, Ji-Oh Mok, Chul Hee Kim, Yeo Joo Kim, Sang Jin Kim, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh, Myung Hi Yoo
Endocrine Research.2017; 42(2): 154. CrossRef
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians
Young Shin Song, Jung Ah Lim, Young Joo Park
Endocrinology and Metabolism.2015; 30(3): 252. CrossRef
Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings
S. H. Jeong, H. S. Hong, J. J. Kwak, E. H. Lee
Journal of Endocrinological Investigation.2015; 38(8): 849. CrossRef

First
Prev
Page of 1
Next
Last

Search